Hidden gem within TLN : 232
More potent, more lucrative and yet less talked about in media is TLN-232.
A revolutionary compound, applying the very basic concept in Oncology: "Cancer cells eats sugar - normal cells don't" (Warburg effect).
The very first approach to treat cancer. taking away the sugar cane....
Well, looks like the current blockbuster cancer drug. The star of the pack Nexavar failed pIII trial for skin cancer...
https://www.reuters.com/article/rbssHealthcareNews/idUSLO61616220090427
TLN is a second generation cancer drug company with 4601 and 232 as lead compounds.
For pharmas, 3 ways to survive the generic threat:
1) merge consolidate and cut cost, cut staff synergy outsourcing R&D (outsourcing part = Caprion = 20% of Caprion held by TLN)
2) Push into niche, protected market, orphan drug status - Niche market = That's TLN shigamab E.coli Shiga toxin neutalizer.
3) Go gang buster into Oncology. Well that goes back into the dire need to get new 2nd generation pipeline drugs. That's 4601 and 232
Now that the pharma world is officially noticing TLN. Not a loud notice yet, but soon we will get details and 15$ per share is a conservative estimate.
Welcome aboard and CHEERS!!!!